Онкогематология (Jun 2017)

GENOTYPING OF AB0 AND Rh SYSTEMS BLOOD GROUPS IN PATIENTS AFTER MULTIPLE HEMOTRANSFUSIONS

  • R. S. Kalandarov,
  • L. L. Golovkina,
  • M. N. Vasilieva,
  • A. G. Stremouchova,
  • T. D. Pushkina,
  • G. V. Atroshchenko,
  • E. N. Parovichnikova

DOI
https://doi.org/10.17650/1818-8346-2017-12-2-70-79
Journal volume & issue
Vol. 12, no. 2
pp. 70 – 79

Abstract

Read online

Introduction. In patients after multiple blood transfusions, the serological determination of ABO and Rhesus blood groups becomes unreliable due to posttransfusion chimerism, i.e., circulation in the blood of two erythrocytes populations – own and donors. To solve this problem helps the genotyping of blood groups. The literature review includes 42 literature sources, including 9 Russian and 33 foreign articles. Materials and methods. The authors typed blood samples of 24 patients with hematological disorders after numerous erythrocyte-containing transfusions. Antigens A and B, Rh D, Rh C/c, Rh E/e were determined by the serological method using monoclonal antibodies anti-A, antiB, anti-D, anti-C, anti-Cw , anti-c, E and anti-e (Moabs) (Hematologist, Russia). The presence of chimerism was established by hemagglutination typing in gel columns ID-Cards «DiaClon ABO / D + Reverse Grouping» and «DiaClon Rh-subgroups + K». The DNA extract was examined by PCR-SSP using commercial primers ABO-TYPE and RH-TYPE (BAG, Germany). Results. In two patients with 50% chimerism with anti-A and anti-B monoclones, the ABO blood group was genotypically identified. Using molecular method presence of Rhesus system antigens was established in 24 patients with 20-95% chimerism for 1-5 antigens. Serological determination of blood groups at 4 months after the cessation of blood transfusions has confirmed all genotyping results. Conclusion. Genotyping is advisable to use to determine the blood groups in patients after numerous erythrocyte-containing transfusions, which allows increasing immunological safety and preventing alloimmunization to clinically significant erythrocytes antigens.

Keywords